In this episode of Pharma Sessions, host Jonathan Kaskey speaks with Lars Dreesmann, the President and Site Head for Boehringer Ingelheim Fremont about how regulatory affairs can impact patient care.

They explore the challenges and opportunities in the regulatory space, including the impact of technology and AI on regulatory affairs and the potential for collaboration between pharmaceutical companies. 

Lars shares his transition from academia to the pharmaceutical industry, the thrill of turning science into tangible products benefiting patients, and the strategic importance of regulatory processes. The conversation delves into how artificial intelligence could revolutionize data management and reporting in pharma manufacturing, and the complexities of producing biosimilars compared to original biologics. The podcast highlights the industry's collaborative spirit, shared goals to enhance drug manufacturing processes, and excitement for future scientific breakthroughs that could lead to curing currently incurable diseases.

00:00 Introduction to Smart Risk Taking
00:24 Welcome to Pharma Sessions
00:43 Guest Introduction: Lars Driessmann
01:20 Lars' Journey from Academia to Pharma Industry
03:01 The Role of Regulatory Processes in Pharma Manufacturing
17:08 The Impact of Technology on Regulatory Affairs
24:12 The Challenges and Opportunities in Biosimilars
34:26 The Future of Pharma Industry: A Look Ahead

Pharma Sessions is hosted by Jonathan Kaskey

Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/

Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com